Compounded Wegovy and Zepbound may disappear under new FDA rules

The end of compounded versions of weight-loss drugs is near, leaving patients scrambling for alternatives.

Some “copycat” versions of popular weight-loss drugs will soon be restricted in the U.S. The change comes as a federal judge declined an injunction that would’ve allowed compounding pharmacies to keep making more affordable versions.